Breakthrough T1D at the 20th Annual Non-Dilutive Funding Summit
The 20th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with representatives from some of the leading funding agencies including DARPA, CDMRP, ATI, NHLBI, NSCEB, NIA and more, giving attendees the opportunity to learn more in-depth about what non-dilutive funding opportunities are available and relevant for their R&D directly from the funding agencies.
Additionally, the 2024 FreeMind Elite honorees took to the stage to present about their companies research and pipelines and their journey to securing non-dilutive funding.
This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences.
Breakthrough T1D
Breakthrough T1D is a dedicated initiative aimed at transforming the lives of individuals with Type 1 diabetes through advocacy, education, and innovative research. By fostering collaboration among healthcare professionals, researchers, and communities, Breakthrough T1D seeks to accelerate advancements in treatment, improve quality of life, and ultimately find a cure. The initiative emphasizes raising awareness about the unique challenges faced by those living with T1D while driving forward impactful solutions that make a real difference.
Alan Chiu, Research Scientist
Alan Chiu is a Research Scientist at BreakthroughT1D, formerly JDRF. BreakthroughT1D provides over $100 million in funding for basic and clinical research in the Type 1 Diabetes space annually. Therapies and technologies that improve the lives or outcomes for T1D patients (including co-morbidities like cardiovascular, kidney, and retinal diseases) or drive towards prevention or a cure are all eligible for funding. Alan has a PhD from Cornell University and has a research background in stem cell biology, islet transplants, and oncology. At his role at BreakthroughT1D, he is responsible for academic and industry outreach and particularly enjoys working with startups and entrepreneurs.
